Asian Pacific Journal of Cancer Prevention

  • 제13권5호
  • /
  • Pages.2193-2197
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Methylenetetrahydrofolate Reductase C677T Polymorphism and Cervical Cancer Risk: a Meta-Analysis

  • Guo, Li-Na (Department of Obstetrics and Gynecology, General Hospital of Tianjin Medical University)
  • 발행 : 2012.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the metabolism of folate, and the role of MTHFR C677T polymorphism in cervical carcinogenesis is still controversial. Method: We performed a meta-analysis of all relevant case-control studies that examined any association between the C677T polymorphism and cervical cancer risk. We estimated summary odds ratios (ORs) with their confidence intervals (CIs) to assess links. Results: Finally, 10 studies with a total of 2113 cervical cancer cases and 2804 controls were included. Results from this meta-analysis showed that significantly elevated cervical cancer risk was associated with the MTHFR T allele in the Asian population under conditions of two genetic comparison models (for TT vs. CC, OR = 1.37, 95%CI 1.00-1.87, P = 0.050; for TT vs. TC+CC: OR = 1.34, 95%CI 1.01-1.77, P = 0.039). However, there was no obvious association between the MTHFR C677T polymorphism and cervical cancer risk in the other populations. Conclusion: The MTHFR C677T polymorphism is associated with cervical cancer risk in Asians, while any possible link in the Caucasian population needs further studies.

키워드

참고문헌

  1. Agodi A, Barchitta M, Cipresso R, et al (2010). Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in sicily. Int J Gynecol Cancer, 20, 141-6. https://doi.org/10.1111/IGC.0b013e3181c20842
  2. Baseman JG, Koutsky LA (2005). The epidemiology of human papillomavirus infections. J Clin Virol, 32, S16-24. https://doi.org/10.1016/j.jcv.2004.12.008
  3. Chansaenroj J, Theamboonlers A, Junyangdikul P, et al (2012). Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev, 13, 599-606. https://doi.org/10.7314/APJCP.2012.13.2.599
  4. Cheng P, Schmutte C, Cofer KF, et al (1997). Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer, 75, 396-402. https://doi.org/10.1038/bjc.1997.64
  5. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  6. Delgado-Enciso I, Martinez-Garza SG, Rojas-Martinez A, et al (2006). [The effect of MTHFR polymorphisms, pregnancy and first intercourse on cervical cancer in a population from the Northeastern Mexico]. Rev Invest Clin, 58, 462-9.
  7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  8. Dong LM, Potter JD, White E, et al (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-36. https://doi.org/10.1001/jama.299.20.2423
  9. Dong X, Wu J, Liang P, et al (2010). Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res, 41, 125-33. https://doi.org/10.1016/j.arcmed.2010.01.001
  10. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  11. Frosst P, Blom HJ, Milos R, et al (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 10, 111-3. https://doi.org/10.1038/ng0595-111
  12. Gerhard DS, Nguyen LT, Zhang ZY, et al (2003). A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. Gynecol Oncol, 90, 560-5. https://doi.org/10.1016/S0090-8258(03)00368-8
  13. Goodman MT, McDuffie K, Hernandez B, et al (2001). Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev, 10, 1275-80.
  14. Goyette P, Sumner JS, Milos R, et al (1994). Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet, 7, 195-200. https://doi.org/10.1038/ng0694-195
  15. Goyette P, Pai A, Milos R, et al (1998). Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mammalian Genome, 9, 652-6. https://doi.org/10.1007/s003359900838
  16. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  17. Hirschhorn JN, Lohmueller K, Byrne E, et al (2002). A comprehensive review of genetic association studies. Genet Med, 4, 45-61. https://doi.org/10.1097/00125817-200203000-00002
  18. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  19. Kang S, Kim JW, Kang GH, et al (2005). Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol, 96, 173-80. https://doi.org/10.1016/j.ygyno.2004.09.031
  20. Kohaar I, Kumar J, Thakur N, et al (2010). Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population. Biomarkers, 15, 61-8. https://doi.org/10.3109/13547500903295881
  21. Lambropoulos AF, Agorastos T, Foka ZJ, et al (2003). Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett, 191, 187-91. https://doi.org/10.1016/S0304-3835(02)00675-4
  22. Li J, Kang LN, Qiao YL (2011). Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev, 12, 1149-53.
  23. Magnusson PK, Sparen P, Gyllensten UB (1999). Genetic link to cervical tumours. Nature, 400, 29-30. https://doi.org/10.1038/21801
  24. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  25. Mostowska A, Myka M, Lianeri M, et al (2011). Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clin Biochem, 44, 596-600. https://doi.org/10.1016/j.clinbiochem.2011.02.007
  26. Mun JY, Han MA, Lee HY, et al (2011). Cervical cancer screening in Korea: report on the National Cancer Screening Programme in 2008. Asian Pac J Cancer Prev, 12, 1961-4.
  27. Munger K, Baldwin A, Edwards KM, et al (2004). Mechanisms of human papillomavirus-induced oncogenesis. J Virol, 78, 11451-60. https://doi.org/10.1128/JVI.78.21.11451-11460.2004
  28. Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27. https://doi.org/10.1056/NEJMoa021641
  29. Nandan NK, Wajid S, Biswas S, et al (2008). Allelic variations in 5, 10-methylenetetrahydrofolate reductase gene and susceptibility to cervical cancer in Indian women. Drug Metab Lett, 2, 18-22. https://doi.org/10.2174/187231208783478498
  30. Piyathilake CJ, Macaluso M, Johanning GL, et al (2000). Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervical intraepithelial neoplasia. Anticancer Res, 20, 1751-7.
  31. Piyathilake CJ, Azrad M, Macaluso M, et al (2007). Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. Nutrition, 23, 229-35. https://doi.org/10.1016/j.nut.2006.12.006
  32. Prasad VV, Wilkhoo H (2011). Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie, 34, 422-6. https://doi.org/10.1159/000331131
  33. Rao GG, Kurien A, Gossett D, et al (2006). A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis. Gynecol Oncol, 101, 250-4. https://doi.org/10.1016/j.ygyno.2005.10.019
  34. Shekari M, Sobti RC, Kordi Tamandani DM, et al (2008). Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population. Arch Gynecol Obstet, 278, 517-24. https://doi.org/10.1007/s00404-008-0623-6
  35. Sull JW, Jee SH, Yi S, et al (2004). The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol, 95, 557-63. https://doi.org/10.1016/j.ygyno.2004.08.008
  36. Taioli E, Garza MA, Ahn YO, et al (2009). Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol, 170, 1207-21. https://doi.org/10.1093/aje/kwp275
  37. Tong SY, Lee JM, Song ES, et al (2010). The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. Cancer Causes Control, 21, 23-30. https://doi.org/10.1007/s10552-009-9430-z
  38. Tong SY, Kim MK, Lee JK, et al (2011). Common polymorphisms in methylenetetrahydrofolate reductase gene are associated with risks of cervical intraepithelial neoplasia and cervical cancer in women with low serum folate and vitamin B12. Cancer Causes Control, 22, 63-72. https://doi.org/10.1007/s10552-010-9675-6
  39. von Keyserling H, Bergmann T, Schuetz M, et al (2011). Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure. Int J Gynecol Cancer, 21, 1664-71. https://doi.org/10.1097/IGC.0b013e31822b6299
  40. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  41. Zacho J, Yazdanyar S, Bojesen SE, et al (2011). Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. Int J Cancer, 128, 644-52. https://doi.org/10.1002/ijc.25375
  42. Zhang J, Qiu LX, Wang ZH, et al (2010). MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls. Breast Cancer Res Treat, 123, 549-55. https://doi.org/10.1007/s10549-010-0783-5
  43. Zoodsma M, Nolte IM, Schipper M, et al (2005). Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Hum Genet, 116, 247-54. https://doi.org/10.1007/s00439-004-1233-4

피인용 문헌

  1. MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies vol.35, pp.5, 2014, https://doi.org/10.1007/s13277-013-1554-9
  2. Association between MTHFR gene 1298A>C polymorphism and breast cancer susceptibility: a meta-analysis based on 38 case-control studies with 40,985 subjects vol.14, pp.1, 2016, https://doi.org/10.1186/s12957-016-0978-2